The move follows similar initiatives by players like Syngene, Laurus Labs, and Aragen. Industry analysts see Bharat Biotech’s ...
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...
A groundbreaking FDA approval offers the first-ever treatment for ultra-rare Thymidine Kinase 2 Deficiency (TK2d). KYGEVVI, a ...
Hyderabad: Bharat Biotech International Ltd has announced the formal launch of Nucelion Therapeutics Pvt Ltd, marking its ...
Dr. Katz's research shows how important it is for all breast cancer survivors to have access to genetic testing services, ...
Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...
Hyderabad: Vaccine maker Bharat Biotech is foraying into the contract research development and manufacturing organisation ...
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as its been in years, some analysts said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback